Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors
Open Access
- 11 May 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (9), 3389
- https://doi.org/10.3390/ijms21093389
Abstract
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate the immune system, aiming at enhancing antitumor immunity. Their clinical efficacy is well-documented, but the side effects associated with their use are still under investigation. These drugs cause several immune-related adverse events (ir-AEs), some of which stand within the field of rheumatology. Herein, we present a literature review performed in an effort to evaluate all publicly available clinical data regarding rheumatic manifestations associated with ICIs. The most common musculoskeletal ir-AEs are inflammatory arthritis, polymyalgia rheumatica and myositis. Non-musculoskeletal rheumatic manifestations are less frequent, with the most prominent being sicca, vasculitides and sarcoidosis. Cases of systemic lupus erythematosus or scleroderma are extremely rare. The majority of musculoskeletal ir-AEs are of mild/moderate severity and can be managed with steroids with no need for ICI discontinuation. In severe cases, more intense immunosuppressive therapy and permanent ICI discontinuation may be employed. Oncologists should periodically screen patients receiving ICIs for new-onset inflammatory musculoskeletal complaints and seek a rheumatology consultation in cases of persisting symptoms.This publication has 123 references indexed in Scilit:
- 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeAnnals Of The Rheumatic Diseases, 2012
- Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndromeArthritis Research & Therapy, 2012
- Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody TherapyAmerican Journal of Roentgenology, 2011
- Neoplastic and Paraneoplastic Vasculitis, Vasculopathy, and HypercoagulabilityRheumatic Disease Clinics of North America, 2011
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanomaInvestigational New Drugs, 2010
- CTLA4 blockade increases Th17 cells in patients with metastatic melanomaJournal of Translational Medicine, 2009
- Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma PatientDermatology, 2009
- CTLA-4 +49A/G and CT60 gene polymorphisms in primary Sjögren syndromeArthritis Research & Therapy, 2007
- Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjögren's syndromeArthritis & Rheumatism, 2006